Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 09:47 pm
Share
Interpace Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 9.35 million compared to USD 11.16 million a year ago. Net loss was USD 3.94 million compared to USD 3.45 million a year ago. Basic loss per share from continuing operations was USD 0.92 compared to USD 0.83 a year ago. Diluted loss per share from continuing operations was USD 0.92 compared to USD 0.83 a year ago. Basic loss per share was USD 0.93 compared to USD 0.84 a year ago. Diluted loss per share was USD 0.93 compared to USD 0.84 a year ago.
For the six months, sales was USD 19.73 million compared to USD 20.99 million a year ago. Net loss was USD 6.19 million compared to USD 7.65 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.84 a year ago. Diluted loss per share from continuing operations was USD 1.44 compared to USD 1.84 a year ago. Basic loss per share was USD 1.47 compared to USD 1.87 a year ago. Diluted loss per share was USD 1.47 compared to USD 1.87 a year ago.
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.